pancreatitis%20-%20acute
PANCREATITIS - ACUTE
Acute pancreatitis is inflammation of the pancreas that occurs suddenly.
Abdominal pain is the most prominent symptom of acute pancreatitis.
It is diagnosed by at least two of the following: characteristic abdominal pain, serum amylase or lipase levels ≥3 times the upper limit of normal and characteristic abdominal imaging findings.
Mild acute pancreatitis does not have any organ failure or local or systemic complication.
Moderately severe acute pancreatitis has the presence of local or systemic complication and/or transient organ failure in <48 hours.
Severe acute pancreatitis has organ failure persistent in >48 hours.

Management of Pancreatic Necrosis

  • Pancreatic necrosis develops in about 1/5 of acute pancreatitis patients and is usually confirmed through CT scanning
  • When patients do not suffer from organ failure or systemic toxicity, pancreatic necrosis may usually be treated conservatively with IV fluids and analgesia
  • Infected necrosis of the pancreas should be suspected in patients who exhibit organ dysfunction or systemic toxicity after 7-10 days
    • Infected necrosis may be diagnosed either by the presence of gas within the pancreatic collection or by FNA
    • CT-guided FNA of the infected necrosis with Gram stain and culture for aerobic and anaerobic bacteria and for fungi should be done if infected necrosis is being considered and to distinguish it from sterile necrosis 
    • If witho CT FNA, empiric antibiotics should be given
    • Patients with necrosis involving >30% of the pancreas may also need to undergo FNA
  •  FNA-confirmed infection may be treated with a step-up approach that includes antibiotics, image-guided drainage, then surgical intervention 
  • Antibiotics should be chosen based on culture and sensitivity results and should penetrate well into the pancreas
  • Patients who develop infection and have previously received prophylactic antibiotics should be considered as having a healthcare-associated infection

Sterile Necrosis

  • Clinically mild and not usually associated with systemic complications
    • Clinically stable patients should be managed non-surgically and antibiotics are not needed
  • If organ failure and systemic toxicity improve, medical therapy should be continued and may consist of systemic antibiotics to prevent secondary pancreatic infection
  • These patients occasionally need surgical intervention but this is uncommon

Infected Necrosis

  • Pancreatic infection calls for prompt debridement or necrosectomy
    • Minimally invasive methods of necrosectomy are preferred to open methods
  • In stable patients, interventions (eg surgical, radiologic and/or endoscopic drainage) should be done after >4 weeks to permit content liquefaction and fibrous wall formation around necrosis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.